Home/Investors/Roivant Sciences

Roivant Sciences

Biotech Investor · 2 portfolio companies

Portfolio
2
Combined Value
$4.7B
Focus Areas
3
Top Stage
Phase 3

Portfolio Companies

CompanyValuation
Immunovant$4.7B
Affimed$3.0M